Medistim ASA (MD1.F)
- Previous Close
16.75 - Open
17.05 - Bid 16.40 x --
- Ask 17.00 x --
- Day's Range
16.40 - 17.05 - 52 Week Range
11.10 - 18.45 - Volume
233 - Avg. Volume
12 - Market Cap (intraday)
306.331M - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
28.28 - EPS (TTM)
0.58 - Earnings Date Aug 20, 2025
- Forward Dividend & Yield 0.52 (3.08%)
- Ex-Dividend Date May 9, 2025
- 1y Target Est
--
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which are designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation; ultrasound imaging probes; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
www.medistim.comRecent News: MD1.F
View MorePerformance Overview: MD1.F
Trailing total returns as of 6/2/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MD1.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MD1.F
View MoreValuation Measures
Market Cap
312.87M
Enterprise Value
299.21M
Trailing P/E
28.75
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.85
Price/Book (mrq)
7.55
Enterprise Value/Revenue
5.71
Enterprise Value/EBITDA
18.97
Financial Highlights
Profitability and Income Statement
Profit Margin
20.35%
Return on Assets (ttm)
17.26%
Return on Equity (ttm)
27.42%
Revenue (ttm)
603.92M
Net Income Avi to Common (ttm)
122.88M
Diluted EPS (ttm)
0.58
Balance Sheet and Cash Flow
Total Cash (mrq)
183.45M
Total Debt/Equity (mrq)
5.61%
Levered Free Cash Flow (ttm)
88.84M